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ABSTRACT  
Aims: To describe the characteristics and time to death of patients with breast or haematologic cancer 
who died of heart failure (HF) after cancer therapy. Patients with an index admission for HF who died 
of HF-related causes (IAHF) and those with no index admission for HF who died of HF-related 
causes (NIAHF) were compared. 
Methods and Results: We performed a linked data analysis of Cancer Registry, Death Registry and 
Hospital Administration records (n=15,987). Index HF admission must have occurred after cancer 
diagnosis. Of the 4894 patients who were deceased (30.6% of cohort), 734 died of HF-related causes 
(50.1% female) of which 279 (38.0%) had at least one IAHF (41.9% female) post-cancer diagnosis. 
Median age was 71 years (IQR 62-78) for IAHF and 66 years (IQR 56-74) for NIAHF. There were 
fewer chemotherapy separations for IAHF patients (median=4, IQR 2-9) compared to NIAHF patients 
(median=6, IQR 2-12). Of the IAHF patients, 71% had died within one year of the index HF 
admission. There was no significant difference in HF-related mortality in IAHF patients compared to 
NIAHF (HR, 1.10, 95%CI, 0.94-1.29, p=0.225) 
Conclusion: The profile of IAHF patients who died of HF-related causes after cancer treatment 
matched the current profile of heart failure in the general population (over half were aged ≥70 years). 
However, NIAHF were younger (62% were aged ≤69 years), female breast cancer patients that died 
of HF-related causes before hospital admission for HF-related causes – a group that may have been 
undiagnosed or undertreated until death. 
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INTRODUCTION  
Anticancer therapies have increased recurrence-free survival for many cancer patients. 
However associated comorbidities and treatment-related toxicity have limited overall survival gains. 
(1) Cardiotoxicity is one of the most significant side-effects of some anticancer agents, so that any 
gain in life expectancy is potentially diminished by increased mortality due to cardiotoxic sequelae 
such as heart failure (HF), myocardial ischaemia, arrhythmias, hypertension, and thromboembolism. 
(1)  
The incidence and outcomes of cardiotoxicity depend on different factors related to 
oncological therapies including the type of drug, the mode of administration (i.e. bolus or continuous), 
dose administered during each cycle, cumulative dose, combinations (or prior treatment) with other 
cardiotoxic drugs or radiotherapy of the cardiac region and patient age, mediastinal radiation, female 
sex, presence of cardiovascular (CV) risk factors and previous cardiovascular disease (CVD). (2,3)  
Cardiotoxicity related to anthracyclines is well documented, with early studies reporting 
variable rates, often based upon retrospective identification in cancer-survivor cohorts. A recent large, 
prospective study, which included regular monitoring of cardiac function, reported an incident rate of 
cardiotoxicity following anthracycline therapy of 9% over a median 5-year follow-up period, (3) with 
98% of these cases occurring in the first 12 months. High mortality rates have also been reported in 
patients with anthracycline-mediated cardiotoxicity identified through historical longitudinal cohorts 
(4). More recent studies have suggested better cardiac-related survival of chemotherapy patients, 
especially in patients identified with pre-symptomatic left ventricular dysfunction (5). This is likely to 
be a result of routine baseline and ongoing monitoring being implemented as standard practice where 
known cardiotoxic drugs are considered. (5) Cardinale et al. (2015) recently reported that left 
ventricular function either partially or completely recovered following early detection and treatment 
in 82% of patients with anthracycline-mediated cardiotoxicity. (3) Torti and colleagues, (6) based on 
histologic evidence of anthracycline cardiotoxicity, showed that only higher doses and frequency of 
Page 4 of 21 
 
anthracycline administration and previous cardiac irradiation were independent risk factors. 
Cumulative doxorubicin dose was also recently confirmed to be an independent risk factor by 
Cardinale et al. (2015), in addition to end-chemotherapy left ventricular ejection fraction. 
Nonetheless, there is wide variation in individual sensitivity to anthracyclines, with some patients 
developing cardiotoxicity at doses as low as 300 mg/m2 body surface area. (3)  
Previous work from our research group, using a linked dataset, demonstrated that in those 
individuals with breast or haematologic cancer (leukaemias, lymphomas and related blood disorders), 
7% of patients previously treated with chemotherapy had an index hospital admission for heart failure 
(HF) (1,062/15,987) within the 14-year study period (Figure 1). (7) Of these patients who had an 
index admission for HF, 68% (728/1062) died within the study period, with 38% (279/728) of deaths 
attributed to HF-related causes. Approximately 93% (14,925/15,987) of individuals did not have an 
index admission for HF following chemotherapy.  
INSERT FIGURE 1 
Of these patients, 28% (4166/14925) had died, with approximately 11% (455/4166) of deaths 
attributed to HF-related causes. Individuals who had no previous index heart failure admission were 
significantly younger and comprised a greater proportion of females compared with patients admitted 
with heart failure. (7) This group was the focus of this study. 
The aim of this sub-analysis was to further explore the characteristics of those patients who 
died of HF-related causes after chemotherapy. As 11% of the cohort described above died of HF-
related causes without an index hospital admission for heart failure, the objectives of this study were 
to:  
1) Identify differences in demographic characteristics between those who died of HF-related 
causes after an index admission for HF (IAHF), compared to those who died of HF-related causes 
without an index admission for HF (NIAHF) and  
2) Identify whether there were differences in HF-related mortality risk between the two 
patient groups.  
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METHODS 
Study design and setting 
This is a retrospective cohort study of patients linked using health data between January 1996 
and December 2009 from Queensland, Australia. Queensland is Australia’s third most populous state 
with an estimated residential population of four million people during the study period. (8) This 
timeframe enabled linkage and analysis of uniform data across the three data sources relating to 
morbidity, hospitalisation, and mortality.  
Ethics approval was granted by the Metro South Service District Human Research Ethics 
Committee on behalf of the Queensland Government (HREC/11/QPAH/600). 
Assumptions of this analysis 
The purpose of this analysis was to review the characteristics of patients who died of heart 
failure after cancer treatment. We used “real world” data from clinical administration datasets using 
data linkage techniques. Data for cardiovascular risk factors, previous disease and details on specific 
dose and chemotherapy agents were not available or obtainable during the process of data abstraction 
and linkage. Therefore, as a surrogate variable to control for confounders (such as a previous 
diagnosis of heart failure) we examined the outcomes of patients who had their first heart failure 
admission after chemotherapy. An index heart failure admission is a first ever recorded admission as 
coded on discharge using ICD9 of ICD10 codes for the classification of heart failure. This is regarded 
as an acceptable criterion for diagnostic confirmation of heart failure. (9)  The comparison group may 
have contained patients with existing heart failure. 
The second assumption of this analysis is that patients with breast or haematologic cancers 
were more likely than patients with other cancers to be treated with cardiotoxic drugs, particularly 
anthracyclines. (3)  
Thirdly while chemotherapy is usually delivered in the outpatient setting, ambulatory care of 
this nature is often recorded as an admission for chemotherapy, which we have used as a surrogate for 
the number of chemotherapy cycles. The assumption of this variable is that all patients in the cohort 
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received chemotherapy for haematologic and breast cancer from 1996 to 2009 but that not all 
chemotherapy cycles have been captured. Outpatient and pharmacotherapy data were not available for 
linkage at the time of our data request.  
Participants 
Primary cancer diagnosis was used to identify the cancer site/morphology using the 
International Classification of Diseases and Tenth Revision Australian Modification (ICD 10-AM) 
and ICD-O (oncology) site codes in the original linked dataset. Cancer sites were defined as breast 
(ICD 10-AM: C50) or haematologic (leukemia, lymphoma and related disorders) (ICD10-AM: C42, 
C77 and ICD-O: M9590/3-M9989/3) henceforth referred to as ‘haematologic cancers’. No age 
exclusions were applied. In this analysis, only patients who had died of HF-related causes were 
included and these patients were then stratified into two groups – those who had their first admission / 
diagnosis for HF as identified by an index admission for HF (IAHF) and those who did not have an 
index HF admission (NIAHF), following commencement of chemotherapy. 
Data sources and linkage 
Data were accessed from the Queensland Cancer Registry, the Hospital Admitted Patient Data 
Collection, and the Queensland Births, Deaths and Marriages database.  
The Queensland Cancer Registry was used to access data on age, sex, marital status, residence 
(rural or metropolitan), country of birth, and Aboriginal or Torres Strait islander status. Primary 
cancer diagnosis was used to identify the cancer type, and the cancer site/morphology was identified 
by applying the relevant site codes from ICD 9 and ICD 10.  
Patients receiving chemotherapy were identified by using chemotherapy-related procedure 
codes from the Hospital Patient Data Collection and linked to the primary cancer diagnoses records 
from the Queensland Cancer Registry. The procedure codes were defined according to ICD-9CM 
(Clinical Modification) and ICD-10-AM (Australian Modification). Cancer morphology codes were 
defined in accordance with uniform ICD-O. Radiotherapy was not considered in this study due to the 
unknown proportion of patients receiving concomitant treatment in an outpatient setting.  
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Selection of patients with an index HF hospitalisation was based upon hospital records with 
patients flagged if they had an admission to hospital for the first time with heart failure coded as the 
principle diagnosis (i.e. ICD-9-CM and ICD-10-AM diagnostic codes). This first admission or “index 
event” must have occurred after the diagnosis of cancer and the commencement of chemotherapy. 
The third database involved in the linkage process was the Queensland Birth, Deaths and 
Marriages database – a complete repository of all registered deaths in the state of Queensland. All 
causes of death underwent a manual recoding from the text entries – a process that underwent quality 
assurance by three independent investigators. The end date of data for study purposes was December 
31, 2009. Deaths after this date were not accounted for and the patients alive at the specified end date 
were considered alive for the purposes of calculating survival times and mortality analyses.  Data 
extraction and coding were undertaken using STATA 13.0.  Linkage Wiz software was used to 
undertake probabilistic record matching. Quality control undertaken during the linkage process 
included a 20-step manual clerical review to identify false positives – a method that quantified the 
false positive rate at 0.3%. (9)  
Statistical analyses 
Based upon the stratification of patients as 1) an index heart failure admission (IAHF) and 2) 
no admission for heart failure (NIAHF), admission groups were compared using 2-contingency table 
testing for categorical variables (age group, sex marital status, country of birth, Indigenous status, 
residence, cancer morphology/site). Age in years was categorised as <20, 20-29, 30-30, 40-49, 50-59, 
60-69, and ≥70 to describe the demographics of the study population and is also presented as a 
continuous variable. Due to the non-normal distribution of the continuous variables (age, 
hospitalisations, chemotherapy treatments), they are presented as medians with IQR and compared 
using the non-parametric Mann-Whitey U test. The effect of an index admission for HF on the risk of 
HF mortality was assessed adjusted for age, sex, marital status, country of birth, cancer site and 
chemotherapy along with other confounders using a time-varying Cox proportional hazards regression 
model. Multivariate adjustment was undertaken for the covariates of age group in years [<20, 20-29, 
30-30, 40-49, 50-59, 60-69, and ≥70], sex, marital status, country of birth, cancer site, and number of 
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chemotherapy separations categorised as quintiles [Q1: 1-3; Q2: 4-6; Q3: 7-9; Q4: 10-16; Q5: ≥17]. 
To examine associations between admission groups, an adjusted Kaplan-Meier survival analysis was 
used with a log-rank test.  All statistical tests were conducted at the 5% significance level and were 
performed using IBM SPSS 22.0. 
RESULTS 
Participants 
A STrengthening the Reporting of Observational studies in Epidemiology (STROBE) 
flowchart describes the allocation of patients to the respective groups for the subsequent analyses 
(Figure 1). (10) A total of 73,158 patients from the Cancer Registry were able to be record-matched 
with hospital administration records and mortality data.  
Of these, 918 were diagnosed with multiple cancers. To avoid duplicating patients in the 
analyses the primary cancer diagnosis was chosen and the remaining registrations of subsequent 
cancers in this group were excluded (n=927). A further 15,750 were excluded as they fell outside the 
study time period, and another 40,494 were excluded as they did not receive chemotherapy.  
The remaining 15,987 patients were then identified as those who had an index HF admission 
(n=1,062), or those who did not have an index HF admission (n=14,925).  
Within each of these groups, those with HF-related death within the study period were 
identified, resulting in the two groups analysed in this study: those with a diagnosed index HF 
admission who died of HF related causes (IAHF, n=279) and those with no index HF admission but 
who died of HF related causes (NIAHF, n=455). 
 
Demographics and Characteristics  
Within the deceased group the median age at cancer diagnosis was 71 and 66 years for the 
IAHF and NIAHF patients respectively (Table 1, p<0.001). There was a significant association 
between age group and HF admission status between these two groups, with the majority of HF 
patients being ≥70 years, while the NIAHF were more evenly spread across the younger age groups 
(2=32.05, df=6, p<0.001). Gender (2=12.11, df=1, p=0.001) and cancer morphology/site (2=25.57, 
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df=1, p<0.001) were also significantly different between the two groups, as were the median number 
of overall hospitalisations for heart failure or chemotherapy (p<0.001) and median number of 
chemotherapy admissions (p<0.001). All other comparisons were non-significant. 
INSERT TABLE 1 
Outcomes 
There was no significant difference in HF-related mortality in IAHF patients compared to 
NIAHF (HR, 1.10, 95%CI, 0.94-1.29, p=0.225) (Figure 2) when adjusted for age, sex, marital status, 
country of birth, cancer site, and number of chemotherapy treatments.  
In the NIAHF group, individuals diagnosed with haematologic cancer were almost 1.5 times 
more likely to die of heart-failure related causes than breast cancer patients (p=0.006) (Table 2).  
A similar odds ratio was evident in the IAHF patients, but was non-significant. The only other 
significant difference was that those in the IAHF group received 4-6 admissions for chemotherapy 
compared to those who had 1-3 admissions (Table 2). All other covariates were non-significant in the 
adjusted models. 
Of those who died of HF-related causes, 31% of IAHF and 33% of NIAHF patients died 
within the first year after the cancer diagnosis and 60% of IAHF and 62% of NIAHF patients had died 
of HF-related causes within three years of cancer registration.  
Of note, of the IAHF patients, 70.6% of patients had died of HF-related causes within the first 
year following their HF diagnosis. 
INSERT FIGURE 2 
INSERT TABLE 2
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DISCUSSION 
In this analysis of linked hospital administration data we have examined the patient journey 
through cancer diagnosis, chemotherapy and the onset of heart failure and ultimately heart failure-
related death. We have described and compared individuals who had an index heart failure hospital 
admission (IAHF) with those who did not have an index -heart failure hospital admission (NIAHF) 
following chemotherapy. All of the patients included in the analyses died of HF-related causes. 
Specifically, we were interested in those patients who died of HF-related causes but were not newly 
diagnosed (index admission) or already had a HF diagnosis.  When comparing characteristics of the 
IAHF and NIAHF patients, the median age, gender differences for the IAHF patients had similar  
demographical characteristic to heart failure in the non-cancer population. (11). That is, the study 
group had a similar median age and a greater proportion of men. (11) In contrast, NIAHF patients 
were younger and had a greater proportion of female patients than males. In addition there was a 
greater proportion of patients with breast cancer in the NIAHF patients compared to the IAHF group. 
Collectively our results indicated that younger, female breast cancer patients died of HF-related 
causes before hospital admission for heart failure related causes. 
The first year following an index HF admission saw the highest mortality, with 71% of 
individuals dying of HF-related causes in that period.  The first year after cancer diagnosis showed 
very similar proportions of patients in both groups dying from HF related causes (30.5% and 33.4% in 
the IAHF and NIAHF respectively). Without supplementary information (see Strengths and 
Limitations below) it is difficult to further explore this finding in more depth. It may be that IAHF 
patients are symptomatic and mortality is high shortly after admission. A possible explanation of 
similar mortality in NIAHF (typically younger patients) is a higher tolerance of HF symptoms and as 
such were not admitted to hospital and sudden death followed due to arrhythmia. Nonetheless, our 
results are comparable with other studies that have demonstrated that 38% of patients with a HF 
diagnosis had died within 12 months. (12) Although not statistically significant, the risk of crude HF 
mortality was about 10% higher for individuals not admitted to hospital with HF compared with those 
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admitted with HF. Whilst it may seem counterintuitive, and one might expect the NIAHF group to 
have a lower proportion of mortality due to HF, a possible explanation could be that those diagnosed 
with HF received some intensive cardiac interventions that reduced their mortality risk in the first 
year. It is possible that extra cardiac treatment is also responsible for comparable proportions of 
mortality due to HF at the end of three years also (60% and 62% in the IAHF and NIAHF 
respectively). These mortality rates are all substantially higher, within all age groups within this 
cohort, than those reported in the most recent epidemiological studies for heart failure in the general 
population where, although survival has improved, the absolute mortality rates for HF remain 
approximately 50% within 5 years of diagnosis. (13, 14) In the ARIC study, the 30-day, 1-year, and 5-
year case fatality rates after hospitalization for HF were 10.4%, 22%, and 42.3%, respectively. (15)  
Over the course of their treatment, IAHF patients received significantly fewer chemotherapy 
treatments than the NIAHF group. This trend could be attributed to clinical adherence to 
cardiotoxicity treatment guidelines, with a commensurate reduction in cumulative chemotherapy dose 
or complete cessation of treatment after HF was identified. (5) However, in the context of a 
retrospective observational study, there are numerous confounders that were beyond our control that 
would need to be accounted for to definitively conclude if this was the case. In addition we may need 
to consider that current available therapies for HF administered earlier in the chemotherapy treatment 
phase are of limited efficacy.  Also, our outcomes may be indicating that the admission index was a 
poor surrogate for efficacy of early introduction of effective therapies. 
 
Strengths and Limitations 
The strengths of this study are the large sample size and the inclusion of virtually all cancer 
patients who underwent chemotherapy over a 14 year period. The ability to link administrative 
datasets allows for the integration of multiple databases to provide a comprehensive picture of patient 
outcomes. However, potential limitations should be considered.  
The nature of this type of study method means that what is gained in overall numbers of 
patients comes at the expense of detailed case information. The direct implication of this is numerous 
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confounding factors cannot be accounted for.  For example, the absence of information regarding the 
cancer treatment, including the precise chemotherapy drugs used and the site and extent of irradiation, 
plus radiotherapy and the lack of information about pre-existing cardiovascular risk factors or 
established heart disease prevents us from understanding the association of specific treatments and the 
subsequent development of HF. Furthermore, in the absence of supplementary data we are unable to 
elucidate the causes of HF-related deaths (e.g. was death due to advanced cardiomyopathy, 
cardiogenic shock, arrhythmia, or electrolytes imbalance due to diuretics?) or the severity of HF 
status. These limitations were due to only being able to access datasets with custodian approval, and 
in an idealised situation more relevant data would have been incorporated in the analysis framework 
(e.g. whether patients were administered appropriate and optimal HF medications). In the absence of 
this data we included chemotherapy separations as a surrogate for drug information. The gender 
balance in our study is not representative of the general population with 31% of the sample being 
male and 69% female. The inclusion of breast cancer patients has resulted in an over-representation of 
female patients. 
 
Clinical Implications  
Current Clinical Practice Guidelines for cardiovascular toxicity after chemotherapy and 
radiotherapy from the European Society of Medical Oncology (ESMO) recommend that patients are 
frequently monitored for cardiovascular risk before, during and after treatment. (5)  These guidelines 
state that both cardiovascular risk factor screening and heart structure and function monitoring, 
including appropriate cardiovascular intervention, should occur prior to cancer treatment. In addition 
cardiac monitoring should continue at baseline, three, six and nine months during treatment and 
further monitoring should be undertaken at 12 and 18 months and followed up at four and ten years. 
In the present study we have identified that HF-related death can occur rapidly after cancer treatment 
in individuals diagnosed with cancers in which cardiotoxic drugs are often prescribed. This finding is 
consistent with the ESMO recommendations of ongoing cardiac monitoring and it is likely with on-
going frequent monitoring appropriate intervention can be implemented to decrease HF-related 
mortality after cancer therapy. 
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Conclusion 
The profile of patients who died of HF-related causes who had an index admission for HF 
after cancer treatment matched the current profile of heart failure in the general population (over half 
were aged ≥70 years). However, the group that did not have an index admission for heart failure were 
younger (62% were aged ≤69 years), females with breast cancer. In this group Heart Failure after 
cancer therapy may have been under-diagnosed or undertreated until death and the heart failure 
caused by the chemotherapy may manifest long after discharge from cancer care. 
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Legend of Tables and Figures  
 
Tables  
1. Table 1: Demographics, Hospitalisation and Chemotherapy Rates for Patients who died of 
HF-related causes by index admission for HF 
2. Table 2: Adjusted time-varying Cox Proportion Hazards Model for HF-related mortality of 
Chemotherapy receiving haematologic and breast cancer patients by index admission for HF. 
Data were adjusted for age, sex, marital status, country of birth, cancer site and time 
dependent number of chemotherapy treatment 
 
Figures  
1. Figure 1: Population selection flow diagram. This diagram displays the initial study 
population through to the final study population. 
2. Figure 2: Time to HF-related death after diagnosis in cancer registry between those who had 
an index admission for HF (IAHF, n=279) compared to those who did not (NIAHF, n=455) 
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Table 1: Demographics, Hospitalisation and Chemotherapy Rates for Patients who died of HF-related 
causes by index admission for HF  
 
Characteristics 
 
Patient with index 
HF admission 
  
N=279 (38.0) 
Patient with no 
admission for HF 
  
 
N=455 (62.0) 
P* 
 
Median Age (at cancer diagnosis) 
IQR 
71.0 year 
62 – 78 
66.0 year 
56 – 74 
<0.001 
Age Group 
   < 20 years  
20-29 years 
30-39 years 
40-49 years 
50-59 years  
60-69 years 
   ≥ 70 years 
 
1 (0.4) 
1 (0.4) 
3 (1.1) 
11 (3.9) 
31 (11.1) 
78 (28.0) 
154 (55.2) 
 
3 (0.7) 
5 (1.1) 
17 (3.7) 
49 (10.8) 
80 (17.6) 
128 (28.1) 
173 (38.0) 
 
<0.001 
 
Sex  
Female 
Male 
 
117 (41.9) 
162 (58.1) 
 
251 (55.2) 
204 (44.8) 
 
0.001 
 
Marital Status 
Married/De Facto 
Single/divorced/widowed 
 
160 (57.3) 
119 (42.7) 
 
273 (60.0) 
182 (40.0) 
 
0.487 
 
Country of Birth 
Australia 
All Other Countries 
 
195 (69.9) 
84 (30.1) 
 
337 (74.1) 
118 (25.9) 
 
0.234 
 
Indigenous Status  
Indigenous 
Non-indigenous 
 
3 (1.1) 
276 (98.9) 
 
10 (2.2) 
445 (97.8) 
 
0.389 
 
Residence (Postcode) 
Metropolitan 
Rural/Remote 
 
244 (87.5) 
35 (12.5) 
 
379 (83.3) 
76 (16.7) 
 
0.138 
 
Cancer Morphology/Site 
Breast 
Haematologic 
 
34 (12.2) 
245 (87.8) 
 
128 (28.1) 
327 (71.9) 
 
<0.001 
 
 
Median No of hospitalisation (IQR) 7 (3 – 13) 6 (2 – 12) <0.001 
Median no of chemotherapy 
separations (IQR) 
4 (2 – 9) 6 (2 – 12) <0.001 
 
IQR indicates interquartile range (25th-75th percentile); SMR, standardised mortality ratio 
* Data were considered significantly different at p≤0.05 
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Table 2: Adjusted time-varying Cox Proportion Hazards Model for HF-related mortality of 
Chemotherapy receiving haematologic and breast cancer patients by index admission for HF. Data 
were adjusted for age, sex, marital status, country of birth, cancer site and time dependent number of 
chemotherapy treatment  
 
  Patient with index HF 
admission 
 
Patient with no HF 
admission 
 
Parameter HR (95% CI) P* HR (95% CI) P* 
Age     
< 20 years †     
20-29 years 0.30 (0.02-5.08) 0.408 0.56 (0.13-2.38) 0.435 
30-39 years 0.26 (0.03-2.56) 0.246 0.47 (0.14-1.67) 0.245 
40-49 years 0.33 (0.04-2.66) 0.295 0.49 (0.15-1.61) 0.240 
50-59 years 0.35 (0.05-2.64) 0.307 0.57 (0.18-1.83) 0.343 
60-69 years 0.46 (0.06-3.40) 0.447 0.44 (0.14-1.40) 0.165 
≥ 70 years 0.44 (0.06-3.19) 0.413 0.50 (0.16-1.58) 0.237 
Sex     
 Female vs male 1.22 (0.89-1.68) 0.221 0.96 (0.75-1.23) 0.754 
Marital status      
Married/de facto vs  all other 0.96 (0.72-1.29) 0.802 0.98 (0.80-1.21) 0.869 
Country of birth     
Australia vs all other  0.86 (0.65-1.14) 0.303 1.15 (0.92-1.44) 0.214 
Cancer Site     
Breast vs Haematologic  1.47 (0.97-2.23) 0.068 1.48 (1.11-1.95) 0.006 
Chemotherapy separations 
(quintiles) 
    
1-3 †     
4-6 0.91 (0.83-0.99) 0.027 0.97 (0.90-1.05) 0.420 
7-9 0.93 (0.83-1.02) 0.152 0.94 (0.87-1.01) 0.102 
10-16 0.92 (0.84-1.02) 0.108 0.98 (0.91-1.06) 0.684 
≥ 17 0.95 (0.86-1.06) 0.364 0.97 (0.90-1.05) 0.479 
HF indicates heart failure; HR, hazard ratio.  
* Statistically significant at p≤0.05 
† Reference category 
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Figure 1: Population selection flow diagram. This diagram displays the initial study population 
through to the final study population. 
 
 
Index admission for heart 
failure 
(n=1,062) 
No index admission for heart 
failure 
(n=14,925) 
All other cause death 
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Figure 2. Time to HF-related death after cancer diagnosis between those who had an index admission 
for HF (IAHF, n=279) compared to those who did not (NIAHF, n=455)  
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